Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1080
- Registration Number
- NCT06191744
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
🇺🇸Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States
REmission in Membranous Nephropathy International Trial (REMIT)
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 224
- Registration Number
- NCT06120673
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Cairns Hospital, Cairns, Queensland, Australia
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06108232
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT06084936
- Locations
- 🇦🇺
Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia
🇦🇺Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia
🇦🇺Epworth Hospital, Richmond, Victoria, Australia
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 640
- Registration Number
- NCT06073821
- Locations
- 🇺🇸
John Muir Medical Center, Concord, California, United States
🇺🇸University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Department of Medicine Hematologyoncology, Los Angeles, California, United States
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University College, London
- Target Recruit Count
- 99
- Registration Number
- NCT06071871
- Locations
- 🇬🇧
Kings College Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧Churchill Hospital, Oxford, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT06054776
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Christine Ryan
- Target Recruit Count
- 66
- Registration Number
- NCT06043674
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Obinutuzumab in Chinese Real-world Patients With iNHL
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 400
- Registration Number
- NCT05968001
- Locations
- 🇨🇳
Wuxi Second People's Hospital, Wuxi, Jiangsu, China
🇨🇳Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China
🇨🇳The First People's hospital of Changzhou, Changzhou, Jiangsu, China
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-05-09
- Target Recruit Count
- 89
- Registration Number
- NCT05950997
- Locations
- 🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.